Excalibur Management Corp Sells 4,244 Shares of Organon & Co. (NYSE:OGN)

Excalibur Management Corp lowered its holdings in Organon & Co. (NYSE:OGN) by 18.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 19,139 shares of the company’s stock after selling 4,244 shares during the period. Excalibur Management Corp’s holdings in Organon & Co. were worth $286,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Horizon Bancorp Inc. IN boosted its holdings in Organon & Co. by 2,401.5% during the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after purchasing an additional 1,585 shares in the last quarter. Millstone Evans Group LLC acquired a new stake in Organon & Co. in the 4th quarter valued at $29,000. Larson Financial Group LLC grew its position in Organon & Co. by 345.4% in the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock valued at $33,000 after acquiring an additional 1,734 shares during the period. Riverview Trust Co raised its stake in Organon & Co. by 117.7% during the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock worth $36,000 after acquiring an additional 1,292 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its stake in Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after acquiring an additional 672 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Trading Down 3.8 %

Shares of NYSE OGN opened at $14.74 on Wednesday. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10. The company has a 50-day moving average of $15.41 and a two-hundred day moving average of $16.33. The company has a market cap of $3.80 billion, a PE ratio of 4.43, a P/E/G ratio of 0.90 and a beta of 0.76. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. As a group, equities analysts expect that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a $0.28 dividend. The ex-dividend date was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.60%. Organon & Co.’s payout ratio is 33.63%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. TD Cowen raised shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Morgan Stanley decreased their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, February 14th. Finally, Barclays cut their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.